Castle Biosciences (NasdaqGM:CSTL) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker6Good afternoon, and welcome to Castle Biosciences's fourth quarter and full year 2025 conference call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question and answer session. I would like to turn the call over to Camilla Zuckero, Vice President, Investor Relations and Corporate Affairs.Speaker1Thank you, operator. Good afternoon, ...

Our Mission: Protect and Save Lives February 26, 2026 1 Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the ob ...

Financial Results and Operational Update for the period ended December 31, 2025 February 2026 ASX: MSB; Nasdaq: MESO For personal use only For personal use only CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements and forecasts that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ mat ...

NovoCure Limited Q4 2025 Earnings Call Summary - Moby Strategic Execution and Operational Evolution Achieved record net revenue of $655 million in 2025, driven by substantial active patient growth in international markets like France and Japan. Transitioned to a multi-indication platform company following the FDA approval of Optune Pax for locally advanced pancreatic cancer in a record 180-day review cycle. Stabilized the core glioblastoma (GBM) business in mature markets, shifting focus toward high ...

Q4 2025 Earnings Call February 26, 2026 Important Information and Disclaimer Where Molecular Science Meets Artificial Intelligence Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements regarding our business, solutions, plans, object ...

Natera, Inc. Q4'2025 Earnings Presentation February 26, 2026 Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our reimbursement coverage and our product costs, our commercial and strategic partnerships and potential acq ...

Q4 & FY 2025 Earnings Call February 26, 2026 Safe harbor disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact could be deemed forward-looking. These forward- looking statements relate to future events or results of Seer, Inc. (the "Company") and involve known and unknown risks, uncertainties and other factors that may cause the actual r ...

Empowering people, informing care decisions February 2026 ©2026 Castle Biosciences 1 Disclaimers Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning: our positioning for continued grow ...

Summary of Voyager Therapeutics FY Conference Call Company Overview - **Company**: Voyager Therapeutics (NasdaqGS: VYGR) - **Industry**: Biotechnology, specifically focusing on gene therapy and treatments for neurodegenerative diseases, particularly Alzheimer's disease Key Points 1. Strategic Focus Areas - **Three Pillars of Value**: - **Tau Target**: Focus on tau as a target for Alzheimer's with two programs: VY7523 (anti-tau antibody) and VY-1706 (gene therapy) [2][3] - **Gene Therapy**: Plans to advance two gene therapy assets into clinical trials, one in partnership with Neurocrine and one wholly owned by Voyager [2] - **NeuroShuttle Platform**: Development of a platform to deliver various drugs across the blood-brain barrier [3] 2. Tau as a Target for Alzheimer's - **Importance of Tau**: The spread of tau in the brain correlates more closely with clinical decline in Alzheimer's than amyloid accumulation [6] - **Recent Developments**: Upcoming data from J&J and Biogen on tau-targeting therapies will provide further validation for tau as a target [5][6] - **Mixed Results from Competitors**: UCB's bepranemab showed some effect on tau spread but failed to meet primary clinical endpoints, indicating the complexity of targeting tau [8][9] 3. Clinical Development Insights - **VY7523**: Preliminary safety data shows a favorable profile, with a brain-to-plasma ratio of 0.3% and a half-life supporting monthly dosing [20] - **MAD Study Design**: The multiple ascending dose (MAD) study is designed to assess the effect on tau PET imaging, which is the key biomarker for evaluating the spread of pathological tau [21] - **Future Studies**: Plans to include tau PET imaging data in future studies and emphasize its importance over fluid-based biomarkers [24][25] 4. Gene Therapy Developments - **VY-1706**: Aiming for a 50%-70% reduction in tau mRNA/protein, with a focus on lower doses to enhance safety and reduce costs [31] - **FDA Interactions**: Productive discussions with the FDA regarding trial designs and plans to file an IND in Q2 2026 [33] 5. NeuroShuttle Platform - **Differentiation**: The ALPL shuttle shows longer half-life and no adverse effects on reticulocyte counts compared to transferrin receptor shuttles, making it a promising delivery method for various therapies [46] - **Therapeutic Modalities**: Exploring antibodies, peptides, and oligonucleotides for use with the NeuroShuttle platform [47] 6. Partnerships and Collaborations - **Neurocrine Partnership**: Progress on gene therapy programs, including FA and GBA1, with plans to enter the clinic this year [48] 7. Market Opportunities - **Alzheimer's Disease**: The potential for anti-tau therapies to be used in combination with anti-amyloid treatments, especially for patients who do not respond to the latter [41] - **Broader Applications**: Potential to address other tauopathies beyond Alzheimer's, expanding the market opportunities for Voyager's therapies [42] Additional Insights - **Clinical Predictions**: Anticipation that BIIB080 will show significant effects in clinical measures, which could influence Voyager's approach to VY-1706 [36] - **Patient Population**: Targeting early Alzheimer's patients for clinical trials, aligning with trends in the amyloid treatment landscape [26][27] This summary encapsulates the key discussions and insights from the Voyager Therapeutics FY Conference, highlighting the company's strategic focus, clinical developments, and market opportunities in the biotechnology sector.

Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in October 2025. Topline results showed TX45 was well tolerated and improved both left heart function and pulmonary hemodynamics in patients with Group 2 PH-HFrEFTX2100 advanced into Phase 1a healthy volunteer clinical trial, randomizing the first subject in February 2026, as a potential treatment for Hereditary He ...